Diabetes, Endocrinology

Diabetes Pen Market Market Insights, Competitive Landscape and Market Forecast–2025

Fri, 05 Feb 2021 15:36:57 +0000

DelveInsight’s ‘Diabetes Pen Market-Market Insights, Competitive Landscape and Market Forecast - 2025’ report delivers an in-depth understanding of Diabetes Pen Market and the historical and forecasted Diabetes Pen Market market trends in the US, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan. The Diabetes Pen Market market report provides an overview of Diabetes Pen Market, reasons to get Diabetes Pen Market as well as its advantages and limitations. Additionally, the report provides insight on the Diabetes Pen Market market share of the individual Diabetes Pen Market devices, current and forecasted Diabetes Pen Market market size from 2017 to 2025 segmented by seven major markets. The report also covers the market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market. Diabetes Pen Market Overview A diabetes pen ensures delivery of insulin in the patient's body in patients suffering from diabeters. The pen is composed of a catridge that carries insulin hormone, a dial to mea...

$4,750.00

Dementia with Diabetes – Pipeline Insight, 2020

Thu, 15 Oct 2020 14:02:56 +0000

DelveInsight’s, “Dementia with Diabetes – Pipeline Insight, 2020,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Dementia with Diabetes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered • Global coverage Dementia with Diabetes Understanding Dementia with Diabetes: Overview Diabetes can cause several complications, such as damage to blood vessels. Diabetes is considered a risk factor for vascular dementia. This type of dementia occurs due to brain damage that is often caused by reduced or blocked blood flow to brain. Many people with diabetes have brain changes that are hallmarks of both Alzheimer's disease and vascular dementia. Some researchers think that each condition fuels the damage caused by the other. There's a lot of research suggesting a connection between diabetes an...

$1,500.00

Diabetes Monitoring, Treatment and Drug Delivery Market | US | 2019-2025 | MedSuite

Wed, 13 Nov 2019 13:39:22 +0000

...

$10,995.00

Diabetes Market Analysis, Size, Trends | Europe | 2019-2025 | MedSuite

Wed, 13 Nov 2019 13:39:22 +0000

...

$13,995.00

Diabetic Gastroparesis - Pipeline Review, H1 2019

Tue, 26 Mar 2019 12:29:57 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Gastroparesis - Pipeline Review, H1 2019, provides an overview of the Diabetic Gastroparesis (Gastrointestinal) pipeline landscape.

Gastroparesis is a long-term complication of diabetes that involves the stomach and affects digestion. Prolonged high blood sugar levels can damage nerves in many parts of the body, including the vagus nerve, which controls contractions of the stomach during digestion. Spasms, abdominal pain, feelings of fullness after a small amount of food, and other symptoms such as nausea and vomiting, reflux, heartburn, and bloating are often experienced with gastroparesis. Loss of appetite and reduced absorption of nutrients may also be experienced. Gastroparesis can lead to weight loss and malnutrition.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Gastroparesis - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development...

$2,000.00

Epiomic Epidemiology Series: Type 1 Diabetes Mellitus Forecast in 12 Major Markets 2017-2027

Mon, 12 Jun 2017 15:35:40 +0000

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Type 1 Diabetes Mellitus in 12 Major Markets Type 1 Diabetes Mellitus (T1DM) is a multisystem disease that progressively destroys the pancreas' ability to produce insulin. This leads to a chronic condition of defective metabolism of fat, carbohydrates and proteins due to the lack of insulin. It occurs mainly in childhood and adolescents, however a rising number of latent autoimmune diabetes of adulthood (LADA) cases have been reported mainly due to a better understanding and diagnosis of the disease. This report provides the current prevalent population for Type 1 Diabetes Mellitus across 12 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Brazil, Japan, India, China and Russia) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity. Providing a value-added level of insight from the analysis team at Black Swan, several of th...

$6,400.00

Epiomic Epidemiology Series: Diabetic Gastroparesis Forecast in 12 Major Markets 2017-2027

Mon, 12 Jun 2017 15:35:40 +0000

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Diabetic Gastroparesis in 12 Major Markets Gastroparesis is a syndrome characterised by delayed gastric emptying in the absence of mechanical obstruction. There is no official classification criterion upon diagnosis. Diabetic gastroparesis affects patients with long-standing diabetes mellitus usually complicated with retinopathy, neuropathy and nephropathy. This report provides the current prevalent population for Diabetic Gastroparesis across 12 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Japan, Brazil, India, China, and Russia) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity. Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Diabetic Gastroparesis have been quantified and presented alongside the overall prevalence figures. These sub-pop...

$5,800.00

Diabetic Nephropathy - Market Insights, Epidemiology and Market Forecast-2023

Tue, 25 Apr 2017 20:08:12 +0000

Note*: This report requires 5-10 business days to complete. DelveInsight’s Diabetic Nephropathy - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Crohn’s disease for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Diabetic Nephropathy forecasted market share for ten years to 2023 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of Diabetic Nephropathy till 2023. Key Coverage and Benefits • The report will help in developing business strategies by understanding the trends shaping and driving the global Diabetic Nephropathy market. • Identifying patient populations in the global “Diabetic Nephropathymarket to improve product design, pricing, and launch plans. • Organize sales and marketing efforts by identifying the best opportunities for Diabetic Nephropathy therapeutics in each of the ...

$4,950.00

Russia Diabetes Care Devices Market Outlook to 2022 - Glucose Monitoring and Insulin Delivery

Wed, 11 Jan 2017 12:42:31 +0000

Summary

GlobalData’s new report, "Russia Diabetes Care Devices Market Outlook to 2022", provides key market data on the Russia Diabetes Care Devices market. The report provides value, in millions of US dollars and volume (in units) within market categories - Glucose Monitoring and Insulin Delivery.

The report also provides company shares and distribution shares data for the market category, and global corporate-level profiles of the key market participants. Based on the availability of data for the particular category and country, information related to pipeline products, news and deals is available in the report.

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.

Scope

- Market size for Diabetes Care Devices market categories - Glucose Monitoring and Insulin Delivery.
- Annualized market revenues (USD million) and volume (units) data for each of the market categories. Data is provided ...

$5,995.00

Diffuse Diabetic Macular Edema Global Clinical Trials Review, H1, 2016

Fri, 16 Sep 2016 20:41:29 +0000

Summary

GlobalData's clinical trial report, “Diffuse Diabetic Macular Edema Global Clinical Trials Review, H1, 2016" provides an overview of Diffuse Diabetic Macular Edema clinical trials scenario. This report provides top line data relating to the clinical trials on Diffuse Diabetic Macular Edema. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an eff...

$2,500.00

Diabetic Peripheral Neuropathy Global Clinical Trials Review, H1, 2016

Fri, 16 Sep 2016 20:41:29 +0000

Summary

GlobalData's clinical trial report, “Diabetic Peripheral Neuropathy Global Clinical Trials Review, H1, 2016" provides an overview of Diabetic Peripheral Neuropathy clinical trials scenario. This report provides top line data relating to the clinical trials on Diabetic Peripheral Neuropathy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an eff...

$2,500.00

Diabetic Nephropathy - Pipeline Review, H2 2016

Thu, 15 Sep 2016 21:22:00 +0000

Summary

Global Markets Direct’s, ‘Diabetic Nephropathy - Pipeline Review, H2 2016’, provides an overview of the Diabetic Nephropathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diabetic Nephropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Nephropathy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC f...

$2,000.00

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Pipeline Review, H2 2016

Thu, 15 Sep 2016 21:22:00 +0000

Summary

Global Markets Direct’s, ‘Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Pipeline Review, H2 2016’, provides in depth analysis on Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted pipeline therapeutics.

The report provides comprehensive information on the Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics development and features dormant an...

$3,500.00

Diabetic Peripheral Neuropathy - Pipeline Review, H2 2016

Thu, 15 Sep 2016 21:22:00 +0000

Summary

Global Markets Direct’s, ‘Diabetic Peripheral Neuropathy - Pipeline Review, H2 2016’, provides an overview of the Diabetic Peripheral Neuropathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diabetic Peripheral Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Peripheral Neuropathy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clini...

$2,000.00

Diabetic Macular Edema - Pipeline Review, H2 2016

Thu, 15 Sep 2016 21:22:00 +0000

Summary

Global Markets Direct’s, ‘Diabetic Macular Edema - Pipeline Review, H2 2016’, provides an overview of the Diabetic Macular Edema pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diabetic Macular Edema, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Macular Edema and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conference...

$2,000.00

Diabetic Neuropathic Pain - Pipeline Review, H2 2016

Thu, 15 Sep 2016 21:22:00 +0000

Summary

Global Markets Direct’s, ‘Diabetic Neuropathic Pain - Pipeline Review, H2 2016’, provides an overview of the Diabetic Neuropathic Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diabetic Neuropathic Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Neuropathic Pain and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries...

$2,000.00

Type 2 Diabetes Mellitus Therapeutics in South-East Asia Markets to 2022 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth

Thu, 15 Sep 2016 20:01:35 +0000

Summary

Diabetes mellitus is a group of metabolic diseases characterized by chronic hyperglycemia - high blood glucose levels - that results from defects in insulin secretion, insulin action, or a combination of these. This chronic hyperglycemia is associated with long-term damage, dysfunction and failure of multiple organs, including the eyes, kidneys, nerves, heart and blood vessels. The vast majority of diabetes mellitus patients can be classified as having either Type 1 Diabetes Mellitus (T1DM) or Type 2 Diabetes Mellitus (T2DM). Approximately 90-95% of all diabetics have T2DM.

T2DM treatment has been revolutionized in the past decade, especially with the increased use of new therapies. The marketed products landscape comprises a wide range of treatment options, including biguanide (metformin), sulfonylureas, thiazolidinediones, GLP-1 receptor agonists, DPP-4 inhibitors, SGLT-2 inhibitors, and insulin therapies. Nevertheless, significant unmet need remains for products that can offer better glycemic control, as well as the prevention and cure of diab...

$4,995.00

Global Diabetes and Obesity Drugs Market to 2022 - Insulins and GPCRs Retain Commercial Prominence, While High Unmet Need Remains in Weight Loss Treatment

Thu, 15 Sep 2016 20:01:35 +0000

Summary

Diabetes is a chronic metabolic disease characterized by hyperglycemia (high blood glucose levels) that results from defects in insulin secretion, insulin action, or both. Chronic hyperglycemia in diabetic patients is associated with long-term damage, dysfunction and failure of multiple organs, including the eyes, kidneys, nerves, heart and blood vessels. The vast majority of diabetes mellitus patients can be classified as having either type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM). Obesity, meanwhile, is defined as abnormal or excessive body fat accumulation that presents a risk to health.

A current global rise in T2DM prevalence is intrinsically linked with the current global rise in obesity. The rapidly increasing global obesity prevalence has resulted in it being considered a global epidemic, and there is a vast and growing global patient population potentially requiring pharmacotherapeutic treatment.

Historically anti-obesity therapeutics have been out of favor due to safety concerns. Both diabetes and obesity products ...

$4,995.00

Frontier Pharma: Diabetic Complications - Innovative and Diverse Neuropathies, Nephropathy and Retinopathies Pipelines Demonstrate Shift Towards Disease Modifying Therapies

Thu, 15 Sep 2016 20:01:35 +0000

Summary

Diabetes is a common long-term condition that can lead to a range of disparate and serious complications. It is a lifelong, multi-systemic condition that affects a number of integral organs. Diabetes has a rapidly increasing prevalence – it currently affects 10% of adults globally, and is estimated to become the seventh-leading cause of death by 2030.

The lack of absolute treatment for the condition and the difficulty in maintaining constant glycemic control, even following adequate treatment, can result in a range of complications. The three main indication groups are diabetic nephropathy, which is a progressive condition caused by damage to the capillaries and kidneys glomeruli as a result of diabetes; diabetic retinopathy, which is defined as damage to the retina as a result of high blood sugar; and a range of diabetic neuropathies, a group of conditions in which nerve damage is caused as a result of diabetes mellitus.

The need for improved therapeutics within diabetic complications is especially prominent in comparison with other multi-sys...

$6,995.00

Diabetic macular edema - Market Insights, Epidemiology and Market Forecast-2023

Wed, 24 Aug 2016 13:19:26 +0000

Note*: This report requires 7-10 business days to complete. Diabetic macular edema - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Diabetic macular edema for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Diabetic macular edema forecasted market share for ten years to 2023 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of Diabetic macular edema till 2023. Key Coverage and Benefits • The report will help in developing business strategies by understanding the trends shaping and driving the global Diabetic macular edema market. • Identifying patient populations in the global “Diabetic macular edema market to improve product design, pricing, and launch plans. • Organize sales and marketing efforts by identifying the best opportunities for Diabetic macular edema therapeutics in ea...

$4,950.00

Diabetic Neuropathy - Market Insights, Epidemiology and Market Forecast-2023

Wed, 24 Aug 2016 13:19:26 +0000

Note*: This report requires 7-10 business days to complete. Diabetic Neuropathy - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Diabetic Neuropathy for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Diabetic Neuropathy forecasted market share for ten years to 2023 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of Diabetic Neuropathy till 2023. Key Coverage and Benefits • The report will help in developing business strategies by understanding the trends shaping and driving the global Diabetic Neuropathy market. • Identifying patient populations in the global “Diabetic Neuropathy market to improve product design, pricing, and launch plans. • Organize sales and marketing efforts by identifying the best opportunities for Diabetic Neuropathy therapeutics in each of the markets cov...

$4,950.00

Diabetic retinopathy - Market Insights, Epidemiology and Market Forecast-2023

Wed, 24 Aug 2016 13:19:26 +0000

DelveInsight’s Diabetic retinopathy - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Diabetic retinopathy for the seven major markets i.e. United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Diabetic retinopathy forecasted market share for ten years to 2023 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of Diabetic retinopathy till 2023. Key Coverage and Benefits • The report will help in developing business strategies by understanding the trends shaping and driving the global Diabetic retinopathy market. • Identifying patient populations in the global Diabetic retinopathy market to improve product design, pricing, and launch plans. • Organize sales and marketing efforts by identifying the best opportunities for Diabetic retinopathy therapeutics in each of the markets covered. • To understand the future market compet...

$4,950.00

Diabetic macular edema (DME)- Market Insights, Epidemiology and Market Forecast-2023

Wed, 24 Aug 2016 13:19:26 +0000

Note*: This report requires 7-10 business days to complete. DelveInsight’s Diabetic macular edema (DME) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Indication for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Diabetic macular edema (DME) forecasted market share for ten years to 2023 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of Diabetic macular edema (DME) till 2023. Key Coverage and Benefits • The report will help in developing business strategies by understanding the trends shaping and driving the global Diabetic macular edema (DME) market. • Identifying patient populations in the global “Diabetic macular edema (DME)market to improve product design, pricing, and launch plans. • Organize sales and marketing efforts by identifying the best opportunities for Diabetic macula...

$4,950.00

Diabetic Gastroparesis Global Clinical Trials Review, H1, 2016

Thu, 23 Jun 2016 09:26:10 +0000

Summary

GlobalData's clinical trial report, “Diabetic Gastroparesis Global Clinical Trials Review, H1, 2016" provides an overview of Diabetic Gastroparesis clinical trials scenario. This report provides top line data relating to the clinical trials on Diabetic Gastroparesis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategie...

$2,500.00

Diabetic Retinopathy - Pipeline Review, H1 2016

Fri, 17 Jun 2016 09:15:01 +0000

Summary

Global Markets Direct’s, ‘Diabetic Retinopathy - Pipeline Review, H1 2016’, provides an overview of the Diabetic Retinopathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diabetic Retinopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Retinopathy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC f...

$2,000.00